Jeffrey F Allen

US Patent:

6989027, Jan 24, 2006

Filed:

Apr 29, 2004

Appl. No.:

10/835153

Inventors:

Jeffrey W. Allen - Santa Rosa CA, US
David S. Brin - Topsfield MA, US
Chris M. Coppin - Carlsbad CA, US

Assignee:

Medtronic Vascular Inc. - Santa Rosa CA

International Classification:

A61F 2/06

US Classification:

623 218, 606200

Abstract:

The percutaneously delivered temporary valve assembly of the present invention, and method of using the same, provides an elongate element and a temporary valve disposed on the elongate element. The temporary valve can comprise struts and a membrane attached to the struts. The elongate element can include at least one lumen. The percutaneously delivered temporary valve assembly can be used to replace an aortic valve by locating a temporary valve in a patient's ascending aorta; deploying the temporary valve; removing the native aortic valve past the temporary valve; implanting the prosthetic aortic valve past the temporary valve; collapsing the temporary valve; and removing the temporary valve from the patient. The temporary valve can be sized to the patient and can be left in place while the prosthetic aortic valve heals in.

US Patent:

7316711, Jan 8, 2008

Filed:

Oct 29, 2003

Appl. No.:

10/694723

Inventors:

Jeffrey Allen - Santa Rosa CA, US
Mark Dolan - Santa Rosa CA, US
Richard Thomas - Cloverdale CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/06

US Classification:

623 115

Abstract:

The present invention is an intralumenal stent device made up of two or more elements. Each element has undulations forming peaks and valleys and is formed from a repeating series including a long segment, a first midsized segment, a short segment, and a second midsized segment. These elements are aligned on a common axis and are connected directly to an adjacent element by a connection. The stent incorporates the advantages of having both long and short segments into a single element.

US Patent:

7318837, Jan 15, 2008

Filed:

Mar 30, 2006

Appl. No.:

11/278052

Inventors:

Michael Krivoruchko - Forestville CA, US
Joseph Lessar - Coon Rapids MN, US
Richard Francis - White Bear Lake MN, US
Matthew Birdsall - Santa Rosa CA, US
Darrel Untereker - Oak Grove MN, US
Jeffrey Allen - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/06

US Classification:

623 115, 424426

Abstract:

A balloon-expandable stent formed from a customized alloy formulation. The stent alloy has a either a high, variable or no work hardening rate, very high modulus of elasticity (Young's modulus), and a low yield point. A stent constructed of a material with this combination of properties undergoes significant plastic deformation upon deployment in vivo to its implantation diameter and exhibits minimum recoil for better sizing. The plastic deformation also raises the subsequent yield point of the stent material resulting in a stronger stent upon implantation that is more resistant to vascular loading.

US Patent:

7523506, Apr 21, 2009

Filed:

Mar 30, 2005

Appl. No.:

11/095807

Inventors:

Subramanya Kumar - Louisville CO, US
Brandon E. Taylor - Longmont CO, US
Jeffrey W. Allen - Denver CO, US
Anshuman Mishra - Westminster CO, US

Assignee:

Sun Microsystems, Inc. - Santa Clara CA

International Classification:

G06F 17/30

US Classification:

726 27, 726 2, 726 26

Abstract:

An approach for managing functionalities within a system generally involves the use of indicators, such as privileges, that are associated with the functionalities. Each functionality is associated with an indicator that is used to determine whether the associated functionality is available for use by an end user. A determination is made that one or more particular functionalities are to be associated with the response because the particular indicator is included in the set of indicators and corresponds to the one or more functionalities. If the system includes functionalities for which indicators are not included in the set of indicators, those functionalities are not reflected in the response. The response is sent so that information regarding the one or more particular functionalities can be displayed via a user interface. In some implementations, an access control mechanism can use privileges for determining functionality availability and privileges for determining user access.

US Patent:

7577477, Aug 18, 2009

Filed:

Apr 29, 2004

Appl. No.:

10/835189

Inventors:

Jeffrey W. Allen - Santa Rosa CA, US
David S. Brin - Topsfield MA, US
Chris M. Coppin - Carlsbad CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61N 1/30
A61M 31/00
A61B 17/08
A61F 2/24

US Classification:

604 21, 604 67, 606213, 623 21

Abstract:

The perivascular leak repair system, and method of using the same, of the present invention provides a sealant reservoir with a repair catheter operably attached; a flow control device disposed between the sealant reservoir and the repair catheter, and the flow control device responsive to a flow control signal; a heart phase detector generating a diastole phase signal; an injection switch generating a injection signal; and a flow controller responsive to the diastole phase signal and the injection signal, and generating the flow control signal. A method of sealing a perivascular leak comprises identifying the perivascular leak; inserting a repair catheter to the perivascular leak; injecting sealant at the perivascular leak; and removing the repair catheter. The sealant can be injected when the heart is in diastole to sweep the sealant into the perivascular leak.

US Patent:

7591848, Sep 22, 2009

Filed:

Apr 6, 2006

Appl. No.:

11/278856

Inventors:

Jeffrey W. Allen - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/24

US Classification:

623 217, 623 21

Abstract:

A system and method for treating a vascular condition includes a conduit having an inner wall defining lumen and a replacement valve device. The replacement valve device includes a prosthetic valve connected to an expandable support structure; the expandable support structure includes at least one valve attachment portion and a plurality of valve attachment devices. Each valve attachment portion includes a plurality of struts, each strut having at least one opening for receiving one of the plurality of valve attachment devices.

US Patent:

7651527, Jan 26, 2010

Filed:

Dec 15, 2006

Appl. No.:

11/611533

Inventors:

Micheal Krivoruchko - Forestville CA, US
Jeffrey Allen - Santa Rosa CA, US
Matthew Birdsall - Santa Rosa CA, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/06

US Classification:

623 138, 623 144, 623 145

Abstract:

A bioresorbable endoluminal prosthesis for placement in a body lumen having a stent substrate of a first metallic material that has a lower electrical potential than a standard reference electrode. The stent substrate is coated with a biodegradable polymer having a second metallic material dispersed therein, wherein the second metallic material has a higher electrical potential than the standard reference electrode. After implantation of the stent within the body lumen, the second metallic material is present in the polymeric coating in a sufficient concentration to cause galvanic corrosion of the first metallic material such that over time the stent substrate is bioresorbed.

US Patent:

8070798, Dec 6, 2011

Filed:

Jul 20, 2007

Appl. No.:

11/780572

Inventors:

Josiah Wilcox - Santa Rosa CA, US
Jeffrey Allen - Santa Rosa CA, US
Scott Doig - Santa Rosa CA, US
Rafaelita Brown - Santa Rosa CA, US

International Classification:

A61F 2/82

US Classification:

623 144

Abstract:

A drug elution stent includes a stent framework and a drug elution portion disposed on the stent framework. The drug elution portion includes a first sugar layer disposed on the stent framework, at least one therapeutic agent layer disposed on the first sugar layer and a second sugar layer disposed on the at least one therapeutic agent layer. A method of manufacturing a drug elution stent includes the steps of providing a stent having a stent framework and coating at least a portion of the stent framework with a drug elution portion. The drug elution portion includes a first sugar layer disposed on the stent framework, at least one therapeutic agent layer disposed on the first sugar layer and a second sugar layer disposed on the at least one therapeutic agent layer.